Source: Annual Congress 2012 - Management of severe respiratory infections
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
O. Kilinc, O. Soylar, A. Cilli, A. Sakar, S. Tasbakan, H. Ellidokuz, B. Celenk, C. Cetinkaya, C. Gunduz, A. Sayiner (Izmir, Antalya, Manisa, Turkey). Comparison of treatment outcomes in community-acquired pneumonia patients treated with beta lactam-macrolide combination versus fluoroquinolone monotherapy. Eur Respir J 2012; 40: Suppl. 56, 2453

Member's Comments

No comment yet.

Related content which might interest you: Combination versus monotherapy for nosocomial pneumonia Source: Eur Respir Rev 2007; 16: 50-55 Year: 2007 Comparison of different models of azithromycin treatment of patients with no severe community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 166s Year: 2006 Monotherapy with β-lactamic antibiotics or macrolides vs their combination for the treatment of community acquired pneumonia (CAP) Source: Annual Congress 2008 - Lower respiratory tract infection: from outbreak to prognostic tests Year: 2008 Efficacy and safety of levofloxacin treatment of community-acquired pneumonia in hospitalized patients Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005 Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia Source: Eur Respir J 2003; 21: 135-143 Year: 2003 Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants Year: 2015 Comparison of conventional and sequential antibiotic therapy of community-acquired pneumonia with levofloxacin and moxifloxacin Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007 The use of piperacillin/tazobactam for treatment of pneumonia in neutropenic patients Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010 Difference of patient background with pneumonia between monotherapy and combination Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011 Efficacy of α-tocoferol in the treatment of patients with pneumonia Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008 Combination therapy (beta-lactam+macrolide) vs fluoroquinolone monotherapy for the treatment of CAP Source: Annual Congress 2012 - Management of severe respiratory infections Year: 2012 Survival benefit of beta-lactam plus macrolide combined therapy versus beta-lactam plus quinolones in hospitalized community-acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies Year: 2016 Fluoroquinolone versus β-lactam plus macrolide in patients hospitalized with community-acquired pneumonia (CAP) Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008 Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP Source: Eur Respir J 2013; 41: 123-130 Year: 2013 The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 733s Year: 2006 A clinical and outcomes assessment of the management of community-acquired pneumonia (CAP): a multinational, prospective, double-blind comparison of moxifloxacin to standard first-line oral monotherapy or combination regimen Source: Eur Respir J 2001; 18: Suppl. 33, 189s Year: 2001 Costs of treatment of hospitalised community-acquired pneumonia from the hospitals’ perspective – a prospective study comparing moxifloxacin with other antibiotic treatment alternatives Source: Eur Respir J 2004; 24: Suppl. 48, 185s Year: 2004 The usage of laferon in treatment of patients with community acquired pneumonia (CAP) Source: Eur Respir J 2007; 30: Suppl. 51, 675s Year: 2007 Efficacy of corticosteroids in hospital treated community-acquired pneumonia Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura Year: 2012 No differences in early or late community-acquired pneumonia outcomes in patients treated with IV ceftriaxone plus oral clarithromycin extended-release tablets versus IV levofloxacin plus oral placebo Source: Eur Respir J 2003; 22: Suppl. 45, 335s Year: 2003